Predictors of Time to Sputum Culture Conversion Among Drug-Resistant Tuberculosis Patients in Oromia Region Hospitals, Ethiopia

References

• World Health Organization Global tuberculosis report 2015 (WHO/HTM/TB/2015.22). Geneva Available from: https://apps.who.int/iris/bitstream/handle/10665/191102/9789241565059_eng.pdf;jsessionid=257E179B7641F5CE7FD14BEF18488436?sequence=1. Accessed 628, 2019.
   Google Scholar
• World Health Organization. Global tuberculosis report 2019. Geneva 2019 Licence: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• World Health Organization. WHO and Global Fund sign cooperation agreement. Strategic Initiative to reach missed TB cases a critical component of grant; 2019 Geneva Available from: https://www.who.int/tb/features_archive/WHO_Global_Fund_agreement/en/. Accessed 812, 2019.
   Google Scholar
• World Health Organization. Public–private mix (PPM) for TB prevention and care [website]; 2018 Geneva Available from: https://www.who.int/tb/areas-of-work/public-private-mix/en/. accessed 251 2020.
   Google Scholar
• Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–1544. doi:10.1016/S0140-6736(16)31012-127733281
   PubMed Web of Science ®Google Scholar
• LoBue P, Sizemore C, Castro KG. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. MMWR Recomm Rep. 2009;58(RR–3):1–43.
   Google Scholar
• WHO. Multidrug-resistant tuberculosis (MDR-TB) In: 2015 UPDATE. Programme Wgt. Geneva: World Health Organization; 2015.
   Google Scholar
• WHO. Definitions and Reporting Framework for Tuberculosis– 2013 Revision. Vol. 2013 Geneva: World Health Organization; 2013.
   Google Scholar
• Callithen N, Matthew N, 2007 United Nations Development Programme (UNDP).
   Google Scholar
• WHO (2019). Tuberculosis key facts. Available from: https://www.who.int/en/news-room/fact-sheets/detail/tuberculosis. Accessed 128, 2020.
   Google Scholar
• United Nations General Assembly. Resolution 73/3: political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. United Nations; 2018 Available from: https://www.un.org/en/ga/search/view_doc.asp?symbol=A/RES/73/3. accessed 286 2019.
   Google Scholar
• World Health Organization. Thirteenth general programme of work, 2019–2023. Geneva 2018 Available from https://apps.who.int/iris/bitstream/handle/10665/324775/WHO-PRP-18.1-eng.pdf. accessed 18 2019.
   Google Scholar
• Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993;329(11):784–791. doi:10.1056/NEJM1993090932911088350889
   PubMed Web of Science ®Google Scholar
• Millard J, Ugarte-Gil C, Moore DA. Multidrug resistant tuberculosis. BMJ. 2015;350(feb26 10):h882. doi:10.1136/bmj.h88225721508
   PubMed Web of Science ®Google Scholar
• Keshavjee S, Farmer PE. Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med. 2012;367(10):931–936. doi:10.1056/NEJMra120542922931261
   PubMed Web of Science ®Google Scholar
• Iang L, Wu Q, Gao L, et al. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax. 2012;67(7):632. doi:10.1136/thoraxjnl-2011-20001822403070
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report 2016. Geneva, Switzerland 2016.
   Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Tuberculosis Surveillance and Monitoring in Europe 2016. Stockholm, Sweden: European Centre for Disease Prevention and Control; 2017.
   Google Scholar
• Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLoS Med. 2012;9(8):e1001300. doi:10.1371/journal.pmed.100130022952439
   PubMed Web of Science ®Google Scholar
• Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42(1):156–168. doi:10.1183/09031936.0013471223100499
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40(6):1430–1442. doi:10.1183/09031936.0002291222496332
   PubMed Web of Science ®Google Scholar
• Günther G, Gomez GB, Lange C, Rupert S, van Leth F; Tbnet. Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey. Eur Respir J. 2015;45(4):1081–1088. doi:10.1183/09031936.0012461425395035
   PubMed Web of Science ®Google Scholar
• World Health Organization. Multidrug-resistant tuberculosis (MDR-TB) indicators. A minimum set of indicators for the programmatic management of MDR-TB in national tuberculosis control programmes. Geneva 2010 WHO/HTM/TB/2010.11; http://whqlibdoc.who.int/hq/2010/WHO_HTM_TB_2010.11_eng.pdf. Accessed 53 2014.
   Google Scholar
• Mulu WMD, Admassu A, Admassu A, Abera B. Risk factors for multi drug resistant tuberculosis patients in Amhara National Regional State. Afr Health Sci. 2015;15(2):368. doi:10.4314/ahs.v15i2.926124781
   PubMed Web of Science ®Google Scholar
• Kanda R, Nagao T, Tho NV, et al. Factors affecting time to sputum culture conversion in adults with pulmonary tuberculosis: historical cohort study without censored cases. PloSone. 2015;10(11):e0142607. doi:10.1371/journal.pone.0142607
   Web of Science ®Google Scholar
• Lee J, Lee BJ, Yoon HI, Lee CT, Lee JH. Influence of previous tuberculosis treatment history on acid fast bacilli smear and culture conversion. Int J Tuberc Lung Dis. 2012;16(10):1344–1348. doi:10.5588/ijtld.12.011323107634
   PubMed Web of Science ®Google Scholar
• Kurbatova E, Gammino V, Bayona J, et al. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16(10):1335–1343. doi:10.5588/ijtld.11.081123107633
   PubMed Web of Science ®Google Scholar
• Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med. 2006;144(9):650–659. doi:10.7326/0003-4819-144-9-200605020-0000816670134
   PubMed Web of Science ®Google Scholar
• Office of the Population and Housing Census Commission, 2008. Summary and statistical report of the 2007 population and housing census: population size by age and sex. Federal Democratic Republic of Ethiopia, Population Census Commission. Ethiopia.
   Google Scholar
• Kebede B, Ayele A, Kassa A, et al. Guidelines on Programmatic Management of Drug Resistant Tuberculosis in Ethiopia. Addis Ababa, Ethiopia: Health FDROEMO;2013.
   Google Scholar
• Federal Ministry of Health of Ethiopia (FMOH). Guideline for Program and Clinical Management of Drug Resistant Tuberculosis. Addis Ababa: FMOH; 2009.
   Google Scholar
• World Health Organization. Guidelines for Establishing DOTS-Plus Pilot Projects for the Management of Multidrug-Resistant Tuberculosis (MDR-TB). Geneva: World Health Organization;2000.
   Google Scholar
• Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrugresistant tuberculosis. Int J Tuberc Lung Dis. 2005;9(6):640–645.15971391
   PubMed Web of Science ®Google Scholar
• Yihunie Akalu T, Muchie KF, Alemu Gelaye K, Munderloh UG. Time to sputum culture conversion and its determinants among multi-drug resistant Tuberculosis patients at public hospitals of the Amhara Regional State: a multicenter retrospective follow up study. PLoS One. 2018;13(6):e0199320–e. doi:10.1371/journal.pone.019932029927980
   PubMed Web of Science ®Google Scholar
• Shibabaw A, Gelaw B, Wang S-H, Tessema B, Cardona P-J. Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia. PLoS One. 2018;13(6):e0198080–e. doi:10.1371/journal.pone.019808029944658
   PubMed Web of Science ®Google Scholar
• Tierney DB, Franke MF, Becerra MC, et al. Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment. PLoSONE. 2014;9(9):e 108035. doi:10.1371/journal.pone.0108035
   Web of Science ®Google Scholar
• Putri FA, Burhan E, Nawas A, et al. Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia. Int J Tuberc Lung Dis. 2014;18(5):564–570. doi:10.5588/ijtld.13.060224903794
   PubMed Web of Science ®Google Scholar
• Lu P, Liu Q, Martinez L, et al. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. Eur Respir J. 2017;49(3):1601558. doi:10.1183/13993003.01558-201628331033
   PubMed Web of Science ®Google Scholar
• Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP. Extensively Drug-Resistant Tuberculosis in the United States, 1993–2007. JAMA. 2008;300(18):2153–2160. doi:10.1001/jama.300.18.2153.19001626
   PubMed Web of Science ®Google Scholar
• Velayutham B, Nair D, Kannan T, et al. Factors associated with sputum culture conversion in multi-drug resistant pulmonary tuberculosis. Int J Tuberc Lung Dis. 2016;20(12):1671–1676. doi:10.5588/ijtld.16.009627931345
   PubMed Web of Science ®Google Scholar
• Rieu R, Chang C, Collin SM, et al. Time to detection in liquid culture of sputum in pulmonary MDR-TB does not predict culture conversion fore arly discharge. J Antimicrob Chemother. 2016;71(3):803–806. doi:10.1093/jac/dkv40726661394
   PubMed Web of Science ®Google Scholar
• Lee HY, Chae KO, Lee CH, et al. Culture conversion rate at 2 months of treatment according to diagnostic methods among patients with culture-positive pulmonary tuberculosis. PLoS One. 2014;9(8):e103768. doi:10.1371/journal.pone.010376825105410
   PubMed Web of Science ®Google Scholar
• Heyckendorf J, van Leth F, Avsar K, et al. Treatment responses in multidrug-resistant tuberculosis in Germany. Int J Tuberc Lung Dis. 2018;22(4):399–406. doi:10.5588/ijtld.17.074129562987
   PubMed Web of Science ®Google Scholar
• Parikh R, Nataraj G, Kanade S, Khatri V, Mehta P. Time to sputum conversion in smear positive pulmonary TB patients on category I DOTS and factors delaying it. J Assoc Physicians India. 2012;60:22–26.
   Google Scholar
• Joseph P, Rao Desai VB, Mohan NS, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res. 2011;133:529–534.21623039
   PubMed Web of Science ®Google Scholar
• Brust JCM, Lygizos M, Chaiyachati K, et al. CultureConversion among HIVCo-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. PLoS One. 2011;6(1):e15841. doi:10.1371/journal.pone.001584121253585
   PubMed Web of Science ®Google Scholar
• Lv L, Li T, Xu K, et al. Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. Infect Drug Resist. 2018;11:147. doi:10.2147/IDR.S15349929416359
   PubMed Web of Science ®Google Scholar
• Akinsola OJ, Yusuf OB, Ige OM, Okonji PE. Models for predicting time to sputum conversion among multi-drug resistant tuberculosis patients in Lagos, South–West Nigeria. Front Public Health. 2018;6:347. doi:10.3389/fpubh.2018.0034730538978
   PubMed Web of Science ®Google Scholar
• Magee MJ, Kempker RR, Kipiani M, et al. Diabetes mellitus, smoking status, and rate of sputum culture conversion in patients with multidrug-resistant tuberculosis: a cohort study from the country of Georgia. PLoS One. 2014;9(4):e94890. doi:10.1371/journal.pone.009489024736471
   PubMed Web of Science ®Google Scholar
• Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest. 2000;117(3):744–751. doi:10.1378/chest.117.3.74410713001
   PubMed Web of Science ®Google Scholar